• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Acute Widespread Rash in a 9-month-old Boy

Poll

What is the cause of this erythematous rash that appeared suddenly and spread rapidly on the child's trunk and extremities?

A 9-month-old boy is seen for an acute, widespread erythematous rash with wheals appearing on trunk and extremities. The child is afebrile, appears well, and the mother reports the rash does not appear to be pruritic. She denies recent illnesses and sick contacts.

What does this rash look like to you?

A. Urticaria
B. Contact dermatitis
D. Erythema multiforme
E. Drug eruption
F. Angioedema
Related Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
ARS Pharma Submits Response to FDA Complete Response Letter for neffy (epinephrine nasal spray) / image credit word map anaphylaxis ©kalpis/stock.adobe.com

ARS Pharma Submits Response to FDA Complete Response Letter for neffy (epinephrine nasal spray)

April 3rd 2024
Article

Positive findings from a repeat dosing study of neffy under nasal allergen challenge conditions will support a potential PDUFA date of October 2, 2024, the company said.

Clinical Focus Business Focus Spotlight TGIF for Optinose Xhance: PDUFA Date Set for Saturday, March 16, 2024 / image credit nasal passages: ©turhanerbas/stock.adobe.com

Optinose Xhance approved by FDA as first medical therapy for CRS

March 15th 2024
Article

Now FDA approved, Optinose’s Xhance is the first nonsurgical option for chronic rhinosinusitis both with and without nasal polyps.

Neffy May be Safe, Effective for Treatment of Urticaria Flares: Daily Dose / image credit: ©New Africa/AdobeStock

Neffy May be Safe, Effective for Treatment of Urticaria Flares: Daily Dose

March 7th 2024
Article

Your daily dose of the clinical news you may have missed.

Needle-free Epinephrine Delivery: Perceptions of Physicians, Patients, and Caregivers / image credit: epipen injection: ©Rob Byron/stock.adobe.com

Needle-free Epinephrine Delivery: Perceptions of Physicians, Patients, and Caregivers

February 27th 2024
Article

AAAAI 2024. Needle phobia is just one of the barriers to not just using an epinephrine autoinjector but to carrying one at all, according to 2 sets of surveys findings.

New Data Suggest neffy May be Safe, Effective for Treatment of Urticaria Flares / Image credit: ©chomplearn 2001/AdobeStock

New Data Suggest neffy May be Safe, Effective for Treatment of Urticaria Flares

February 26th 2024
Article

AAAAI 2024. In patients with treatment-resistant chronic spontaneous urticaria, neffy 1 mg and 2 mg resulted in improvement in itch, hives, urticaria, and erythema scores 5 minutes after dosing.

Neffy Generates Favorable PK/PD Data Under Nasal Allergen Challenge in Repeat Dosing Study Requested by FDA / image credit pollen, allergy: ©jovan vitanovski/shutterstock.com

Neffy Generates Favorable PK/PD Data Under Nasal Allergen Challenge in Repeat Dosing Study Requested by FDA

February 26th 2024
Article

neffy (epinephrine nasal spray) delivered a PK and PD profile greater than or similar to that of IM epinephrine after extreme nasal challenge, reports ARS Pharmaceuticals.

© 2024 MJH Life Sciences

All rights reserved.